DSF/Cu inhibited ubiquitination-mediated proteasomal degradation of xCT, leading to its accumulation, and suppressing this compensatory xCT increase enhanced the sensitivity of HCC cells to DSF/Cu, offering a potential strategy to overcome drug resistance and improve tumor therapy. Here, SLC7A11 is linked to neoplasm.